Royce & Associates LP Purchases 64,049 Shares of Cellebrite DI Ltd. $CLBT

Royce & Associates LP raised its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 214.3% during the third quarter, Holdings Channel reports. The firm owned 93,942 shares of the company’s stock after purchasing an additional 64,049 shares during the period. Royce & Associates LP’s holdings in Cellebrite DI were worth $1,741,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of CLBT. Financial Management Professionals Inc. acquired a new stake in shares of Cellebrite DI during the third quarter worth $28,000. CWM LLC grew its holdings in Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares during the period. PNC Financial Services Group Inc. grew its holdings in Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares during the period. Toth Financial Advisory Corp bought a new position in shares of Cellebrite DI in the 3rd quarter worth about $38,000. Finally, Pacer Advisors Inc. lifted its stake in shares of Cellebrite DI by 523.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock valued at $51,000 after purchasing an additional 2,303 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Up 7.3%

NASDAQ CLBT opened at $15.19 on Friday. Cellebrite DI Ltd. has a 52 week low of $11.76 and a 52 week high of $20.86. The business has a 50 day moving average price of $15.67 and a 200-day moving average price of $16.95. The company has a market cap of $3.79 billion, a price-to-earnings ratio of 49.00, a P/E/G ratio of 2.17 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. Cellebrite DI’s revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 EPS. On average, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on CLBT shares. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Lake Street Capital increased their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Finally, Bank of America raised their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.